NC
HRMY icon

NinePointTwo Capital’s Harmony Biosciences HRMY Stock Holding History

NinePointTwo Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$474K Buy
+14,686
New +$410K 0.19% 45

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

NinePointTwo Capital's HRMY Position: Q4 2023 in Review

NinePointTwo Capital opened a new position in Harmony Biosciences (HRMY) in Q4 2023: 14,686 shares worth $474K. The stake represents 0.19% of the portfolio and ranks #45 among its holdings.

221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

  • NinePointTwo Capital held 14,686 shares of Harmony Biosciences worth $474K as of Q4 2023.
  • Harmony Biosciences was a new NinePointTwo Capital position in Q4 2023.
  • Harmony Biosciences made up 0.19% of NinePointTwo Capital's portfolio in Q4 2023, its #45 holding.
  • 221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.